Published in J Biol Chem on February 05, 2010
Detection and quantification of microparticles from different cellular lineages using flow cytometry. Evaluation of the impact of secreted phospholipase A2 on microparticle assessment. PLoS One (2015) 0.90
Phospholipases A2 and neural membrane dynamics: implications for Alzheimer's disease. J Neurochem (2011) 0.87
Relationship between membrane permeability and specificity of human secretory phospholipase A(2) isoforms during cell death. Biochim Biophys Acta (2011) 0.85
Quantitation of lysolipids, fatty acids, and phospholipase A2 activity and correlation with membrane polarity. J Lipid Res (2012) 0.81
Investigation into the role of phosphatidylserine in modifying the susceptibility of human lymphocytes to secretory phospholipase A(2) using cells deficient in the expression of scramblase. Biochim Biophys Acta (2012) 0.79
Integrated lipidomics in the secreted phospholipase A(2) biology. Int J Mol Sci (2011) 0.79
Partitioning of lysolipids, fatty acids and their mixtures in aqueous lipid bilayers: solute concentration/composition effects. Biochim Biophys Acta (2013) 0.79
Molecular details of membrane fluidity changes during apoptosis and relationship to phospholipase A(2) activity. Biochim Biophys Acta (2012) 0.78
Surface dilution kinetics of phospholipase A(2) catalyzed lipid-bilayer hydrolysis. J Phys Chem B (2014) 0.77
Characterization of crude Echis carinatus venom-induced cytotoxicity in HEK 293T cells. J Venom Res (2011) 0.77
Lactadherin inhibits secretory phospholipase A2 activity on pre-apoptotic leukemia cells. PLoS One (2013) 0.77
In vitro anti-Plasmodium falciparum properties of the full set of human secreted phospholipases A2. Infect Immun (2015) 0.75
Relation between various phospholipase actions on human red cell membranes and the interfacial phospholipid pressure in monolayers. Biochim Biophys Acta (1975) 2.42
Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med (2004) 2.10
Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem (2002) 2.08
Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell (1995) 1.99
Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem (2001) 1.67
A role for oxidative stress in apoptosis: oxidation and externalization of phosphatidylserine is required for macrophage clearance of cells undergoing Fas-mediated apoptosis. J Immunol (2002) 1.56
Mammalian non-pancreatic phospholipases A2. Biochim Biophys Acta (1993) 1.52
Decreased membrane phospholipid packing and decreased cell size precede DNA cleavage in mature mouse B cell apoptosis. J Immunol (1994) 1.50
Exogenously added human group X secreted phospholipase A(2) but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. J Biol Chem (2000) 1.39
A new class of phospholipases A2 with lysine in place of aspartate 49. Functional consequences for calcium and substrate binding. J Biol Chem (1984) 1.38
Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A(2). J Biol Chem (2001) 1.34
Simultaneous analysis of immunophenotype and apoptosis of murine thymocytes by single laser flow cytometry. Cytometry (1992) 1.33
Interfacial enzymology of glycerolipid hydrolases: lessons from secreted phospholipases A2. Annu Rev Biochem (1995) 1.26
Role of charge properties of bacterial envelope in bactericidal action of human group IIA phospholipase A2 against Staphylococcus aureus. J Biol Chem (2002) 1.25
Mass-spectrometric characterization of phospholipids and their primary peroxidation products in rat cortical neurons during staurosporine-induced apoptosis. J Neurochem (2008) 1.13
The antibacterial properties of secreted phospholipases A2: a major physiological role for the group IIA enzyme that depends on the very high pI of the enzyme to allow penetration of the bacterial cell wall. J Biol Chem (2001) 1.13
Roles of Trp31 in high membrane binding and proinflammatory activity of human group V phospholipase A2. J Biol Chem (1999) 1.10
Lipid peroxidation and phospholipase A2 activity in liposomes composed of unsaturated phospholipids: a structural basis for enzyme activation. Biochim Biophys Acta (1988) 1.09
Physical properties of erythrocyte ghosts that determine susceptibility to secretory phospholipase A2. J Biol Chem (2001) 1.08
Mechanisms by which intracellular calcium induces susceptibility to secretory phospholipase A2 in human erythrocytes. J Biol Chem (2001) 1.06
Oleandrin induces apoptosis in human, but not in murine cells: dephosphorylation of Akt, expression of FasL, and alteration of membrane fluidity. Mol Immunol (2006) 1.05
Oxidative lipidomics of programmed cell death. Methods Enzymol (2008) 1.05
The perturbed membrane of cells undergoing apoptosis is susceptible to type II secretory phospholipase A2 to liberate arachidonic acid. Biochim Biophys Acta (1997) 1.05
Definition of the specific roles of lysolecithin and palmitic acid in altering the susceptibility of dipalmitoylphosphatidylcholine bilayers to phospholipase A2. Biochemistry (1998) 1.03
Mechanisms governing the level of susceptibility of erythrocyte membranes to secretory phospholipase A2. Biophys J (2005) 1.02
In vivo protective role of human group IIa phospholipase A2 against experimental anthrax. J Immunol (2005) 1.02
On the binding preference of human groups IIA and X phospholipases A2 for membranes with anionic phospholipids. J Biol Chem (2002) 1.02
Mass-spectrometric analysis of hydroperoxy- and hydroxy-derivatives of cardiolipin and phosphatidylserine in cells and tissues induced by pro-apoptotic and pro-inflammatory stimuli. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.00
High bactericidal efficiency of type iia phospholipase A2 against Bacillus anthracis and inhibition of its secretion by the lethal toxin. J Immunol (2004) 0.98
Mechanisms by which elevated intracellular calcium induces S49 cell membranes to become susceptible to the action of secretory phospholipase A2. J Biol Chem (1999) 0.98
Antibacterial effects of human group IIA and group XIIA phospholipase A2 against Helicobacter pylori in vitro. APMIS (2006) 0.97
Crystal structure of human group X secreted phospholipase A2. Electrostatically neutral interfacial surface targets zwitterionic membranes. J Biol Chem (2002) 0.97
Differential kinetics of propidium iodide uptake in apoptotic and necrotic thymocytes. Histochemistry (1993) 0.95
Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications. Adv Cancer Res (2007) 0.94
Plasma membrane alterations during apoptosis: role in corpse clearance. Antioxid Redox Signal (2004) 0.93
Potential roles of membrane fluidity and ceramide in hyperthermia and alcohol stimulation of TRAIL apoptosis. Apoptosis (2007) 0.93
Mechanisms by which thionin induces susceptibility of S49 cell membranes to extracellular phospholipase A2. Biochim Biophys Acta (1997) 0.93
Calcium ionophores can induce either apoptosis or necrosis in cultured cortical neurons. Neuroscience (1999) 0.93
Susceptibility of S49 lymphoma cell membranes to hydrolysis by secretory phospholipase A(2) during early phase of apoptosis. Biochim Biophys Acta (2000) 0.92
Binding of phospholipase A2 to zwitterionic bilayers is promoted by lateral segregation of anionic amphiphiles. Biochim Biophys Acta (1989) 0.92
Relationship between membrane physical properties and secretory phospholipase A2 hydrolysis kinetics in S49 cells during ionophore-induced apoptosis. Biophys J (2007) 0.91
Sequence of physical changes to the cell membrane during glucocorticoid-induced apoptosis in S49 lymphoma cells. Biophys J (2009) 0.90
Action of human group IIa secreted phospholipase A2 on cell membranes. Vesicle but not heparinoid binding determines rate of fatty acid release by exogenously added enzyme. J Biol Chem (1998) 0.90
Thermodynamic and kinetic studies of the interaction of vesicular dipalmitoylphosphatidylcholine with Agkistrodon piscivorus piscivorus phospholipase A2. J Biol Chem (1989) 0.89
Bacterial expression and characterization of human secretory class V phospholipase A2. Biochem J (1998) 0.88
Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to Apc Min/+ tumorigenesis. Oncogene (2005) 0.86
Enhanced interfacial catalysis and hydrolytic specificity of phospholipase A2 toward peroxidized phosphatidylcholine vesicles. Arch Biochem Biophys (1993) 0.85
Tryptophan-containing mutant of human (group IIa) secreted phospholipase A2 has a dramatically increased ability to hydrolyze phosphatidylcholine vesicles and cell membranes. Biochemistry (1998) 0.85
Effect of tryptophan insertions on the properties of the human group IIA phospholipase A2: mutagenesis produces an enzyme with characteristics similar to those of the human group V phospholipase A2. Biochemistry (2003) 0.83
Fas/FasL-independent activation-induced cell death of T lymphocytes from HIV-infected individuals occurs without DNA fragmentation. Cell Immunol (2001) 0.82
Cell membrane dynamics and the induction of apoptosis by lipid compounds. FEBS Lett (1999) 0.82
The effect of anions on interfacial binding and activation of secretory phospholipase A2. Biochem Soc Trans (1995) 0.80
Membrane fluidity increases during apoptosis of sheep ileal Peyer's patch B cells. Can J Physiol Pharmacol (1996) 0.79
Purification and assay of mammalian group I and group IIa secretory phospholipase A2. Methods Mol Biol (1999) 0.78
Reversibility of the activation of soluble phospholipase A2 on lipid bilayers: implications for the activation mechanism. Biochim Biophys Acta (1992) 0.76
Teaching cell biology in the large-enrollment classroom: methods to promote analytical thinking and assessment of their effectiveness. Cell Biol Educ (2003) 5.52
Computational design of an enzyme catalyst for a stereoselective bimolecular Diels-Alder reaction. Science (2010) 4.32
Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem (2004) 4.10
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med (2008) 3.33
Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci U S A (2005) 3.30
Coronary calcium measurements: effect of CT scanner type and calcium measure on rescan reproducibility--MESA study. Radiology (2005) 3.08
Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem (2008) 2.94
Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci U S A (2005) 2.85
Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I. Clin Chem (2008) 2.48
Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol (2006) 2.45
5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol Pharmacol (2008) 2.24
Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin Chem (2005) 2.17
High-throughput assay of 9 lysosomal enzymes for newborn screening. Clin Chem (2013) 2.09
Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem (2002) 2.08
Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2005) 2.05
Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease. Clin Chem (2004) 1.99
Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med (2007) 1.96
Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis (2006) 1.96
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem (2005) 1.81
Protein cross-linking analysis using mass spectrometry, isotope-coded cross-linkers, and integrated computational data processing. J Proteome Res (2006) 1.81
Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem (2009) 1.73
Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem (2001) 1.67
A tandem mass spectrometry triplex assay for the detection of Fabry, Pompe, and mucopolysaccharidosis-I (Hurler). Clin Chem (2010) 1.65
The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem (2005) 1.60
Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem (2007) 1.60
Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. Biochemistry (2007) 1.56
Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol (2009) 1.56
Regulation and function of epithelial secreted phospholipase A2 group X in asthma. Am J Respir Crit Care Med (2013) 1.51
A strategy of rapid cardioversion minimizes the significance of early recurrent atrial tachyarrhythmias after ablation for atrial fibrillation. J Cardiovasc Electrophysiol (2011) 1.51
Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr (2013) 1.51
Activation of cytokine production by secreted phospholipase A2 in human lung macrophages expressing the M-type receptor. J Immunol (2005) 1.49
Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. J Med Chem (2008) 1.49
Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice. Atherosclerosis (2010) 1.48
Temporary esophageal stenting allows healing of esophageal perforations following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol (2006) 1.44
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43
Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem (2006) 1.38
Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res (2005) 1.36
Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A(2). J Biol Chem (2001) 1.34
Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Anal Chem (2010) 1.34
Use of laurdan fluorescence intensity and polarization to distinguish between changes in membrane fluidity and phospholipid order. Biochim Biophys Acta (2002) 1.34
A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci U S A (2003) 1.34
Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis IVA. Clin Chem (2010) 1.33
Sustained activation of proton channels and NADPH oxidase in human eosinophils and murine granulocytes requires PKC but not cPLA2 alpha activity. J Physiol (2006) 1.32
Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic attendees in Johannesburg, South Africa. Vaccine (2010) 1.31
Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis II (Hunter Syndrome). Anal Chem (2010) 1.29
Interfacial enzymology of parvovirus phospholipases A2. J Biol Chem (2004) 1.28
COPI acts in both vesicular and tubular transport. Nat Cell Biol (2011) 1.28
Role of charge properties of bacterial envelope in bactericidal action of human group IIA phospholipase A2 against Staphylococcus aureus. J Biol Chem (2002) 1.25
Rethinking exams and letter grades: how much can teachers delegate to students? CBE Life Sci Educ (2006) 1.23
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother (2008) 1.21
Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res (2004) 1.21
Improved sensitivity mass spectrometric detection of eicosanoids by charge reversal derivatization. Anal Chem (2010) 1.20
Structural genomics of pathogenic protozoa: an overview. Methods Mol Biol (2008) 1.20
Quantification of DeQi sensation by visual analog scales in healthy humans after immunostimulating acupuncture treatment. Am J Chin Med (2007) 1.20
Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem (2005) 1.18
Tandem mass spectrometry in the detection of inborn errors of metabolism for newborn screening. Methods Mol Biol (2007) 1.18
Absolute quantification of specific proteins in complex mixtures using visible isotope-coded affinity tags. Anal Chem (2004) 1.16
Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness. Am J Respir Crit Care Med (2007) 1.15
Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr Opin Investig Drugs (2005) 1.14
A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. EMBO Mol Med (2010) 1.13
The antibacterial properties of secreted phospholipases A2: a major physiological role for the group IIA enzyme that depends on the very high pI of the enzyme to allow penetration of the bacterial cell wall. J Biol Chem (2001) 1.13
Design and synthesis of substrates for newborn screening of Maroteaux-Lamy and Morquio A syndromes. Bioorg Med Chem Lett (2010) 1.11
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem (2010) 1.11
Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians. Pacing Clin Electrophysiol (2009) 1.10
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem (2009) 1.10
Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol (2010) 1.09
Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother (2012) 1.08
Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators. J Exp Med (2013) 1.08
Protonation sites and dissociation mechanisms of t-butylcarbamates in tandem mass spectrometric assays for newborn screening. J Mass Spectrom (2011) 1.07
Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis. Nat Immunol (2013) 1.06
A ruler for determining the position of proteins in membranes. J Am Chem Soc (2005) 1.06
Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. Mol Biochem Parasitol (2010) 1.06
Tilt and rotation angles of a transmembrane model peptide as studied by fluorescence spectroscopy. Biophys J (2009) 1.05
Lysosomal storage disorder 4+1 multiplex assay for newborn screening using tandem mass spectrometry: application to a small-scale population study for five lysosomal storage disorders. Clin Chim Acta (2012) 1.05
Pathway-oriented profiling of lipid mediators in macrophages. Biochem Biophys Res Commun (2005) 1.05
Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum. Biochim Biophys Acta (2005) 1.05
Role of phosphorylation and basic residues in the catalytic domain of cytosolic phospholipase A2alpha in regulating interfacial kinetics and binding and cellular function. J Biol Chem (2009) 1.04
Inhibition of the complete set of mammalian secreted phospholipases A(2) by indole analogues: a structure-guided study. Bioorg Med Chem (2004) 1.04
Cellular arachidonate-releasing function of novel classes of secretory phospholipase A2s (groups III and XII). J Biol Chem (2003) 1.04
Transglutaminase 2, a novel regulator of eicosanoid production in asthma revealed by genome-wide expression profiling of distinct asthma phenotypes. PLoS One (2010) 1.04
Group V secretory phospholipase A2 modulates phagosome maturation and regulates the innate immune response against Candida albicans. J Immunol (2009) 1.03
Mechanisms governing the level of susceptibility of erythrocyte membranes to secretory phospholipase A2. Biophys J (2005) 1.02
Use of thermal melt curves to assess the quality of enzyme preparations. Anal Biochem (2009) 1.02
On the binding preference of human groups IIA and X phospholipases A2 for membranes with anionic phospholipids. J Biol Chem (2002) 1.02
2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. J Med Chem (2008) 1.01
Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin Cancer Res (2008) 1.01
Localization and function of cytosolic phospholipase A2alpha at the Golgi. Biochimie (2010) 1.01
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chem Rev (2014) 1.00
Arachidonate release and eicosanoid generation by group IIE phospholipase A(2). Biochem Biophys Res Commun (2002) 1.00
Improved reagents for newborn screening of mucopolysaccharidosis types I, II, and VI by tandem mass spectrometry. Anal Chem (2014) 0.99
A designed probe for acidic phospholipids reveals the unique enriched anionic character of the cytosolic face of the mammalian plasma membrane. J Biol Chem (2004) 0.99
The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding. J Med Chem (2006) 0.99
Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol Biochem Parasitol (2006) 0.99
Function, activity, and membrane targeting of cytosolic phospholipase A(2)zeta in mouse lung fibroblasts. J Biol Chem (2007) 0.99